Afatinib therapy: Practical management of adverse events with an oral agent for non-small cell lung cancer treatment Journal Article


Authors: Edwards, R. L.; Andan, C.; Lalla, R. V.; Lacouture, M. E.; O’Brien, D.; Sequist, L. V.
Article Title: Afatinib therapy: Practical management of adverse events with an oral agent for non-small cell lung cancer treatment
Abstract: BACKGROUND: Afatinib is an oral, irreversible ErbB family blocker indicated for first-line treatment of metastatic non-small cell lung cancer (NSCLC) in patients with non-resistant epidermal growth factor receptor (EGFR) mutations. Afatinib is also approved for the treatment of metastatic squamous NSCLC following progression on platinum-based chemotherapy. Common afatinib-associated toxicities include gastrointestinal and dermatologic events, which can be dose limiting. OBJECTIVES: In this review, the authors describe clinical trial experiences with afatinib, as well as best practices and practical approaches to the management of afatinib-associated adverse events in EGFR mutation-positive NSCLC. METHODS: Safety and tolerability data from phase 3 trials of afatinib were reviewed, together with real-life experiences from the authors’ clinical practices. FINDINGS: Patient education, combined with early assessment and effective management of afatinib-related adverse events as well as dosereduction strategies, allows patients to continue treatment and maximize the clinical benefits of afatinib. © 2018, Oncology Nursing Society. All rights reserved.
Keywords: non-small cell lung cancer; adverse events; afatinib; dose reduction
Journal Title: Clinical Journal of Oncology Nursing
Volume: 22
Issue: 5
ISSN: 1092-1095
Publisher: Oncology Nursing Society (ONS)  
Date Published: 2018-10-01
Start Page: 542
End Page: 548
Language: English
DOI: 10.1188/18.cjon.542-548
PROVIDER: scopus
PUBMED: 30239509
DOI/URL:
Notes: Review -- Export Date: 3 December 2018 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Mario E Lacouture
    250 Lacouture